Efficacy and safety of inclisiran, evolocumab and alirocumab in patients with high, very high and extreme cardiovascular risk by N. G. Lozhkina, N. P. Dobrovolskaya, S. N. Artemenko, M. V. Shipunov, A. D. Sharonin, V. A. Koltyugina, V. S. Timofeev, M. I. Voyevoda

Get full text